FI973089A - Ihmisen interleukiini-1-reseptorin apuproteiini - Google Patents

Ihmisen interleukiini-1-reseptorin apuproteiini Download PDF

Info

Publication number
FI973089A
FI973089A FI973089A FI973089A FI973089A FI 973089 A FI973089 A FI 973089A FI 973089 A FI973089 A FI 973089A FI 973089 A FI973089 A FI 973089A FI 973089 A FI973089 A FI 973089A
Authority
FI
Finland
Prior art keywords
human interleukin
auxiliary protein
receptor
receptor auxiliary
protein
Prior art date
Application number
FI973089A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973089A0 (fi
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI973089A0 publication Critical patent/FI973089A0/fi
Publication of FI973089A publication Critical patent/FI973089A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI973089A 1995-01-23 1997-07-22 Ihmisen interleukiini-1-reseptorin apuproteiini FI973089A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23
PCT/EP1996/000181 WO1996023067A1 (en) 1995-01-23 1996-01-17 Human interleukin-1 receptor accessory protein

Publications (2)

Publication Number Publication Date
FI973089A0 FI973089A0 (fi) 1997-07-22
FI973089A true FI973089A (fi) 1997-07-22

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973089A FI973089A (fi) 1995-01-23 1997-07-22 Ihmisen interleukiini-1-reseptorin apuproteiini

Country Status (19)

Country Link
EP (1) EP0808365A1 (hu)
JP (1) JPH10512453A (hu)
AR (1) AR003919A1 (hu)
AU (1) AU4537096A (hu)
BR (1) BR9606837A (hu)
CA (1) CA2210724A1 (hu)
CO (1) CO4480033A1 (hu)
CZ (1) CZ208197A3 (hu)
EA (1) EA199700265A1 (hu)
FI (1) FI973089A (hu)
HU (1) HUP9702458A2 (hu)
IL (1) IL116796A0 (hu)
MX (1) MX9705501A (hu)
NO (1) NO973404D0 (hu)
PE (1) PE64396A1 (hu)
PL (1) PL321538A1 (hu)
TR (1) TR199700652T1 (hu)
WO (1) WO1996023067A1 (hu)
ZA (1) ZA96333B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU741330B2 (en) * 1997-04-30 2001-11-29 F. Hoffmann-La Roche Ag Rat ST38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
WO1999032626A1 (en) 1997-12-23 1999-07-01 Immunex Corporation Sigirr dna and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2002253842A1 (en) 2000-10-31 2002-08-28 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
DK1729810T3 (en) 2004-04-02 2018-12-03 Swedish Orphan Biovitrum Ab Publ PROCEDURE FOR REDUCING AGGREGATION OF IL-1RA
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2607113C (en) * 2004-05-05 2013-11-12 Valorisation-Recherche, Societe En Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20110044894A1 (en) 2008-03-26 2011-02-24 Cellerant Therapeutics, Inc. Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
DK3020730T3 (en) 2011-01-19 2019-04-15 Cantargia Ab ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATMENT OF SOLID TUMORS
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
US20150030586A1 (en) * 2011-06-21 2015-01-29 Sarah Ellen Warren Compositions and methods for the therapy and diagnosis of cancer
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
WO2022247937A1 (en) * 2021-05-28 2022-12-01 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric il1rap

Also Published As

Publication number Publication date
BR9606837A (pt) 1998-05-26
NO973404L (no) 1997-07-23
IL116796A0 (en) 1996-05-14
FI973089A0 (fi) 1997-07-22
MX9705501A (es) 1997-10-31
EP0808365A1 (en) 1997-11-26
JPH10512453A (ja) 1998-12-02
EA199700265A1 (ru) 1998-04-30
CZ208197A3 (en) 1997-11-12
PL321538A1 (en) 1997-12-08
HUP9702458A2 (hu) 1998-04-28
AR003919A1 (es) 1998-09-30
ZA96333B (en) 1996-07-23
NO973404D0 (no) 1997-07-23
TR199700652T1 (xx) 1998-02-21
WO1996023067A1 (en) 1996-08-01
CA2210724A1 (en) 1996-08-01
PE64396A1 (es) 1997-01-28
AU4537096A (en) 1996-08-14
CO4480033A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
FI973089A0 (fi) Ihmisen interleukiini-1-reseptorin apuproteiini
DE69634703D1 (de) Mehrfach einstellbare Sitzeinheit
DE69634739D1 (de) Höhenverstellbares armlehnengefüge
DE69612316T2 (de) Gelenkige Armlehne
DE69528180T2 (de) Modifiziertes molkeprotein
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
DE69517674D1 (de) Verstellbare Sitzanordnung
FI955400A0 (fi) Tuoli
DE69615850D1 (de) G-protein-gekoppelter rezeptor hnfd578
KR970007965U (ko) 의자
KR970019006U (ko) 의자
KR960030269U (ko) 좌의자
KR970007961U (ko) 의자용 이색판
FI103946B1 (fi) Istuin
KR970008134U (ko) 휠체어용 방석
BR7502674U (pt) Cadeira relax
SE9503962D0 (sv) Ställbart ryggstöd
IT240237Y1 (it) Sedia smontabile
KR970015433U (ko) 쐐기형 인류 크램프
KR970007957U (ko) 의자
KR970026773U (ko) 의자
KR960026611U (ko) 등받이대
KR970031423U (ko) 릴렉스 시트
KR960028635U (ko) 시트용 진동기
KR960036852U (ko) 탈착이 용이한 아암레스트